Every Form 4 that Bed Bath & Beyond, Inc. (BBBY) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BBBY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BBBY filings page.
BED BATH & BEYOND, INC. director and executive chairman & CEO Marcus Lemonis purchased common stock in an open-market or private transaction. He acquired 23,094 shares on 2026-08-12 at a weighted average price of $4.30 per share, with individual trade prices ranging from $4.29 to $4.37 per share. Following this transaction, his directly held position increased to 736,232 common shares.
LaRose Brian reported acquisition or exercise transactions in this Form 4 filing.
Bed Bath & Beyond, Inc. reported that Chief Financial Officer Brian LaRose received a grant of 388,889 Restricted Stock Units (RSUs) on August 6, 2026. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in four equal installments on each of the first, second, third and fourth anniversaries of April 28, 2026, subject to continued service through each vesting date. Vested shares will be delivered promptly after vesting, and following this award LaRose beneficially owns 388,889 RSUs from this grant.
Bed Bath & Beyond director Robert Jacob Shapiro purchased 3,000 shares of Common Stock on August 6, 2026 at $4.51 per share, in a transaction classified as a purchase in the open market or a private transaction. Following this trade, he directly holds 70,107 shares. The Rule 10b5-1 trading-plan checkbox for this filing was left unchecked.
Bed Bath & Beyond director Joseph J. Tabacco Jr. reported buying 20,000 shares of Common Stock on August 6, 2026 at a weighted average price of $4.57 per share, from multiple trades between $4.55 and $4.58. After this purchase, he directly owns 58,379 shares and reports indirect beneficial ownership of 167,209 shares held by the Joseph Tabacco and Peggy Schmidt Revocable Trust. The filing indicates the transaction was not made under a Rule 10b5-1 trading plan.
Bed Bath & Beyond Executive Chairman & CEO Marcus Lemonis reported an open-market purchase of 43,382 shares of Common Stock on August 5, 2026, at a weighted average price of $4.67 per share. The shares were bought in multiple trades between $4.64 and $4.74 per share, and his direct holdings increased to 713,138 shares following this transaction.
BED BATH & BEYOND, INC. director Joanna M. Burkey reported an open-market sale of 9,943 shares of common stock on June 4, 2026 at a weighted average price of $6.38 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 5, 2026, indicating it was scheduled in advance. Following this transaction, Burkey directly holds 32,474 shares of the company’s common stock.
BED BATH & BEYOND, INC. director Tamara Ward reported a compensation-related equity grant. She received 36,105 restricted stock units, each representing a contingent right to receive one share of common stock. These restricted stock units vest at the close of business on May 14, 2027, with vested shares delivered promptly after vesting.
Following this grant, Ward beneficially owns 36,105 restricted stock units from the reported award, all held as a direct interest. This is not an open‑market purchase or sale but a grant, award, or other acquisition as part of her role with the company.
Bed Bath & Beyond’s former Chief Accounting Officer Leah R. Putnam reported multiple equity compensation events in the company’s common stock. On May 14, 2026, she exercised performance shares and restricted stock units into a total of 75,013 shares of common stock, while 18,268 shares were disposed of at $4.69 per share to cover tax liabilities. She also received a grant of 1,068 restricted stock units, which were approved by shareholders on May 14, 2026. Footnotes state that several restricted stock units and performance shares had their vesting accelerated in connection with her departure from the company, with vested shares to be delivered promptly after vesting.
Bed Bath & Beyond director Barclay Corbus reported several equity compensation moves. On May 15, 2026, he exercised 26,873 restricted stock units into common shares, bringing his direct common stock holdings to 105,047 shares.
He also received a new grant of 35,181 restricted stock units on May 14, 2026, which will vest at the close of business on May 14, 2027. In addition, he holds 7,816 common stock warrants originally issued on October 7, 2025, each allowing purchase of one common share at an exercise price of $15.50 per warrant through October 7, 2026.
Bed Bath & Beyond director William Benjamin Nettles Jr. reported compensation-related equity transactions, with no open-market buying or selling. On May 15, 2026, restricted stock units covering 26,873 shares of common stock vested and were delivered, increasing his direct common stock holdings to 49,747 shares.
On May 14, 2026, he received a new grant of 35,181 restricted stock units, each representing a contingent right to one share of common stock that vests at the close of business on May 14, 2027. The filing also notes 2,286 common stock warrants originally issued on October 7, 2025 as a pro‑rata distribution to all common shareholders, each with a $15.50 exercise price.
Bed Bath & Beyond director Robert Jacob Shapiro increased his equity stake through compensation-related stock transactions. On May 15, 2026, 26,873 restricted stock units vested and were converted into the same number of common shares at no cost, bringing his direct common stock holdings to 67,107 shares.
On May 14, 2026, he received a new award of 35,181 restricted stock units, each representing a right to one future common share that vests on May 14, 2027. He also holds 4,022 common stock warrants, each allowing the purchase of one share at an exercise price of $15.50 per share, originally distributed pro rata to all common stockholders in October 2025.
Bed Bath & Beyond director Joanna M. Burkey reported compensation-related equity activity. On May 15, 2026, 26,873 restricted stock units vested and were delivered as common shares, bringing her directly held common stock to 42,417 shares. The day before, she received a new grant of 35,181 restricted stock units that vest on May 14, 2027. She also holds 1,554 common stock warrants, each exercisable for one share at an exercise price of $15.50, from a pro-rata distribution originally issued on October 7, 2025.
Bed Bath & Beyond director Debra Golding Perelman reported equity compensation activity, acquiring shares through RSU vesting and receiving new awards. On May 15, 2026, 26,873 restricted stock units converted into the same number of common shares at a price of $0.00, increasing her direct common stock holdings to 32,174 shares.
On May 14, 2026, she received a grant of 35,181 restricted stock units, each representing a contingent right to one common share that vests at the close of business on May 14, 2027. She also holds 530 common stock warrants that were originally issued on October 7, 2025 in a pro-rata distribution to all common shareholders, each exercisable for one common share at an exercise price of $15.50 per warrant until October 7, 2026.
Bed Bath & Beyond director Joseph J. Tabacco Jr. reported compensation-related equity activity. On May 15, 2026, restricted stock units covering 26,873 shares of common stock vested and were converted into the same number of common shares, increasing his directly held stock.
On May 14, 2026, he also received a new grant of 35,181 restricted stock units, each representing a contingent right to one share of common stock that will vest on May 14, 2027. After these transactions, he holds 38,379 common shares directly, plus 167,209 common shares indirectly held by the Joseph Tabacco and Peggy Schmidt Revocable Trust, along with 35,181 RSUs from the new grant.
LEMONIS MARCUS reported acquisition or exercise transactions in this Form 4 filing.
Bed Bath & Beyond, Inc. executive chairman and CEO Marcus Lemonis received a grant of 1,500,000 restricted stock units, each representing a contingent right to one share of common stock. The grant was approved by shareholders on May 14, 2026, after being originally granted on March 11, 2026.
The restricted stock units vest in four equal installments at the close of business on January 1, 2027, January 1, 2028, January 1, 2029, and January 1, 2030, with vested shares delivered promptly after each vesting date. Following this transaction, Lemonis is shown as beneficially owning 1,500,000 restricted stock units from this grant.
Dubois Lisa Foley reported acquisition or exercise transactions in this Form 4 filing.
Bed Bath & Beyond, Inc. Chief Operating Officer Lisa Foley Dubois received a grant of 227,273 restricted stock units, each representing one share of common stock. The RSUs were granted on April 2, 2026, subject to shareholder approval, which was obtained on May 14, 2026.
The award vests in four equal installments at the close of business on April 2, 2027, April 2, 2028, April 2, 2029, and April 2, 2030, with shares delivered promptly after each vesting date. Following this grant, she beneficially owns 227,273 RSUs from this award.
Sullivan Amy Ervin reported acquisition or exercise transactions in this Form 4 filing.
Bed Bath & Beyond, Inc. reported that its President, Amy Ervin Sullivan, received a grant of 454,545 restricted stock units, each representing one share of common stock. The RSUs were granted on April 2, 2026, subject to shareholder approval, which was obtained on May 14, 2026.
The RSUs vest in four equal installments at the close of business on April 2, 2027, April 2, 2028, April 2, 2029 and April 2, 2030, with vested shares delivered promptly after each vesting date. Following this grant, Sullivan beneficially owns 454,545 RSUs from this award.
BED BATH & BEYOND, INC. Chief Accounting Officer Leah R. Putnam exercised restricted stock units into common shares and had shares withheld for taxes. On April 12, 2026, 1,500 restricted stock units converted into 1,500 shares of common stock at a stated price of $0.00 per share. Of these, 366 shares were automatically disposed of at $4.69 per share to cover tax obligations, leaving her with 17,688 shares of common stock held directly after the transactions. The footnote explains these restricted stock units vested in three equal installments on April 12 of 2024, 2025, and 2026, with vested shares delivered promptly after each vesting date, and that the amounts shown reflect restricted stock units from this grant beneficially owned following the reported transaction.
Bed Bath & Beyond, Inc. Chief Operating Officer Lisa Foley Dubois reported receiving a stock award of 14,160 shares of common stock. The award, recorded at a price of $0.00 per share, leaves her holding 14,160 shares directly after the transaction.
The acquisition stems from a merger with The Brand House Collective, Inc. Under an Agreement and Plan of Merger, each TBHC common share she held and each TBHC restricted share unit was converted into Bed Bath & Beyond common stock at a 0.1993-for-1 exchange ratio, with shares also used to satisfy tax withholding.
BED BATH & BEYOND, INC. President Amy Ervin Sullivan reported acquiring 95,255 shares of the company’s common stock on April 2, 2026. The shares were received at $0.00 per share, reflecting stock and restricted share unit conversion terms under a previously signed merger agreement with The Brand House Collective, Inc. using a 0.1993 exchange ratio. Following this transaction, she directly holds 95,255 common shares.
Bed Bath & Beyond director Joseph J. Tabacco Jr. reported an open-market purchase of 20,000 shares of Common Stock at a weighted average price of $5.11 per share. The shares were bought on March 10, 2026 in multiple trades between $5.07 and $5.13 per share.
The purchase was made indirectly through the Joseph Tabacco and Peggy Schmidt Revocable Trust, where he is trustee and beneficiary. After this transaction, the trust held 167,209 shares, and he also held 11,506 shares directly.
The filing also notes previously issued warrants from October 7, 2025, covering 1,150 shares directly and 14,720 shares indirectly, each exercisable for one share of common stock at an exercise price of $15.50 per warrant, with an expiration date of October 7, 2026.
Lee Adrianne reported acquisition or exercise transactions in this Form 4 filing.
Bed Bath & Beyond, Inc. President & CFO Adrianne Lee received a grant of 100,000 restricted stock units (RSUs), each representing a contingent right to one share of common stock. This is a compensation-related award, not an open-market stock purchase or sale.
The RSUs vest in three equal installments at the close of business on February 17, 2027, February 17, 2028 and February 17, 2029. Vested shares will be delivered to Lee promptly after each vesting date, and the 100,000 RSUs shown reflect the amount from this grant beneficially owned following the reported transaction.
Putnam Leah R reported acquisition or exercise transactions in this Form 4 filing.
BED BATH & BEYOND, INC. Chief Accounting Officer Leah R. Putnam reported receiving a grant of 40,000 restricted stock units (RSUs), each representing a right to one share of common stock. These RSUs vest in three equal installments on February 17, 2027, February 17, 2028, and February 17, 2029, with shares delivered promptly after each vesting date. Following this grant, she beneficially owns 40,000 RSUs from this award.
Bed Bath & Beyond executive chairman and CEO Marcus Lemonis reported a series of equity compensation transactions on March 10, 2026. He exercised 166,666 restricted stock units and 141,432 performance shares into an equal number of common shares at a conversion price of $0.00 per share.
He also received common stock awards of 166,666 and 141,432 shares, while 59,813 and 34,680 shares were withheld at $4.91 per share to cover tax obligations. After these vesting and tax-withholding transactions, Lemonis directly holds 669,756 shares of Bed Bath & Beyond common stock.
Bed Bath & Beyond Chief Accounting Officer Leah R. Putnam reported routine equity compensation activity. On March 2, 2026, 1,000 restricted stock units were exercised into 1,000 shares of common stock at a price of $0.00 per share. As part of the same event, 244 shares of common stock at $5.18 per share were withheld to cover tax obligations. Each restricted stock unit represents one share of common stock and vested in three equal installments on March 2, 2024, March 2, 2025 and March 2, 2026. Following these transactions, Putnam directly owned 16,554 shares of Bed Bath & Beyond common stock.
Bed Bath & Beyond Executive Chairman and CEO Marcus Lemonis reported new equity awards. On February 4, 2026, he acquired 424,300 performance shares, each representing the right to receive one share of common stock, at a stated value of $0.001 per performance share.
These performance shares were originally granted on March 10, 2025 and are scheduled to vest in three equal installments on March 10, 2026, March 10, 2027, and March 10, 2028, based on continued service and previously determined performance results for fiscal 2025. The filing also reports 45,615 common stock warrants that were issued on October 7, 2025 as a pro‑rata distribution to all common shareholders, each with an exercise price of $15.50 per warrant.
Bed Bath & Beyond, Inc. President & CFO Lee Adrianne reported multiple equity award vestings and related share transactions on February 4, 2026. Restricted stock units and performance shares converted into common stock at a nominal exercise price of $0.0001–$0.001 per share as they vested.
To satisfy tax withholding obligations, the company withheld shares of common stock at a price of $5.62 per share under transaction code "F". After all reported conversions and tax-withholding transactions, Lee Adrianne directly owned 108,377 shares of Bed Bath & Beyond common stock.
Bed Bath & Beyond’s Chief Accounting Officer Leah R. Putnam reported multiple equity award vesting and related share transactions on February 4, 2026. Restricted stock units and performance shares converted into common stock at nominal exercise prices of $0.001 or $0.0001 per share.
To cover tax obligations on these vestings, the company withheld blocks of common shares at a price of $5.62 per share under transaction code "F". Following the reported transactions, Putnam continued to hold directly beneficially owned common stock and derivative awards, with vesting of remaining earned performance shares and RSUs scheduled through February 4, 2028, subject to service and performance conditions.
Bed Bath & Beyond (BBBY) President & CFO Adrianne Lee reported equity award activity and a warrant grant. On January 23, 2026, 20,965 restricted stock units vested and were converted into the same number of common shares at a nominal exercise price of $0.0001 per share. After this transaction, Lee directly held 81,399 common shares.
On the same date, 6,049 shares of common stock were withheld and disposed of at $6.87 per share in a transaction coded "F," which typically reflects shares withheld to cover taxes, leaving Lee with 75,350 common shares. The Form 4 also reports 6,043 common stock warrants, originally issued on October 7, 2025 as a pro‑rata distribution to all common shareholders, each allowing the purchase of one share at an exercise price of $15.50 per warrant.
Bed Bath & Beyond (BBBY) reported an equity award to a senior executive. On 11/14/2025, an officer serving as Executive Vice President, Chief Digital, Product, and Technology Officer received 116,686 restricted stock units (RSUs) of Bed Bath & Beyond common stock at a price of $0 per unit.
Each RSU represents a contingent right to receive one share of common stock. The award vests in three equal installments at the close of business on November 3, 2026, November 3, 2027 and November 3, 2028, with vested shares to be delivered to the executive promptly after each vesting date. Following this grant, the executive holds 116,686 derivative securities directly.
Bed Bath & Beyond (BBBY) Chief Accounting Officer, who files individually, reported equity award activity and a warrant distribution. On 11/15/2025, the officer acquired 1,186 shares of common stock at an exercise price of $0.0001 through the vesting and settlement of restricted stock units, and disposed of 289 shares at $6.03, typically reflecting shares withheld or sold to cover taxes. Following these transactions, the officer directly holds 3,077 shares of common stock.
In the derivative table, the officer shows 26,906 restricted stock units beneficially owned after the reported RSU conversion, each representing one share of common stock, vesting in two equal installments on November 15, 2025 and November 15, 2026. The officer also acquired 218 common stock warrants with a $15.50 exercise price from an October 7, 2025 pro-rata distribution to all common shareholders, which become exercisable once an S-3 registration statement for the warrant shares is declared effective and remain exercisable through October 7, 2026.
Bed Bath & Beyond Inc.'s Chief Operating Officer reported equity transactions reflecting routine compensation activity. On 11/15/2025, 1,186 shares of common stock were acquired upon the vesting and settlement of restricted stock units at an exercise price of $0.0001 per share, and 343 shares were disposed of at $6.03 per share, typically consistent with tax withholding. Following these transactions, the reporting person directly owned 8,793 common shares and indirectly held 66 shares through a 401(k) plan balance as of 11/17/2025.
In the derivative table, 1,186 restricted stock units converted into common stock, leaving 43,143 derivative securities reported as beneficially owned. The filing also lists 794 common stock warrants with an exercise price of $15.50 per share, originally issued on 10/07/2025 as a pro-rata distribution. These warrants will become exercisable once a Form S-3 registering the underlying shares is declared effective by the SEC and may be exercised through 10/07/2026.